Psyence Biomedical Ltd. Warrant (PBMWW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Nov 20, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PBMWW SEC filings page.
This page shows Psyence Biomedical Ltd. Warrant (PBMWW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Psyence Biomedical Ltd. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
For every $1 of reported earnings, Psyence Biomedical Ltd. Warrant used $3.69 of operating cash (-$3.7M OCF vs $1.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Psyence Biomedical Ltd. Warrant reported -$753K in net income in Q2 2026. This represents a decrease of 632.4% from the same quarter a year earlier.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Psyence Biomedical Ltd. Warrant held $7.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Psyence Biomedical Ltd. Warrant's ROE was -6.3% in Q2 2026, measuring profit generated per dollar of shareholder equity.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
PBMWW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Income Tax, EPS (Basic), EPS (Diluted).
PBMWW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q4'2510-Q | Q2'2510-Q | Q4'2410-K | Q2'2410-K | Q4'2310-K | Q4'2210-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $12.8M+468.5% | $7.3M+546.2% | $2.3M | $1.1M-28.8% | N/A | $1.6M-13.1% | $1.8M |
| Current Assets | $7.6M+240.1% | $6.6M+482.3% | $2.2M | $1.1M-29.2% | N/A | $1.6M-13.1% | $1.8M |
| Cash & Equivalents | $7.1M+270.0% | $6.1M+736.8% | $1.9M+219.2% | $733K-45.0% | $605K | $1.3M-23.9% | $1.8M |
| Total Liabilities | $943K-73.1% | $594K-95.1% | $3.5M | $12.1M+576.0% | N/A | $1.8M+1260.3% | $132K |
| Long-Term Debt | N/A | N/A | N/A | $10.4M | N/A | N/A | N/A |
| Total Equity | $11.9M+1045.5% | $6.7M+161.3% | -$1.3M-27.7% | -$11.0M-5374.1% | -$983K | -$200K-111.8% | $1.7M |
| Retained Earnings | -$58.4M-7.2% | -$56.4M+1.8% | -$54.5M | -$57.5M-812.1% | N/A | -$6.3M-103.6% | -$3.1M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities.
PBMWW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
PBMWW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.
Where Psyence Biomedical Ltd. Warrant Ranks
Frequently Asked Questions
Is Psyence Biomedical Ltd. Warrant profitable?
Yes, Psyence Biomedical Ltd. Warrant (PBMWW) reported a net income of $1.0M in fiscal year 2025.
What is Psyence Biomedical Ltd. Warrant's return on equity (ROE)?
Psyence Biomedical Ltd. Warrant (PBMWW) has a return on equity of 15.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Psyence Biomedical Ltd. Warrant's free cash flow?
Psyence Biomedical Ltd. Warrant (PBMWW) recorded an outflow of $3.7M in free cash flow during fiscal year 2025. This represents a -26.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Psyence Biomedical Ltd. Warrant's operating cash flow?
Psyence Biomedical Ltd. Warrant (PBMWW) recorded an outflow of $3.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Psyence Biomedical Ltd. Warrant's total assets?
Psyence Biomedical Ltd. Warrant (PBMWW) had $7.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Psyence Biomedical Ltd. Warrant's capital expenditures?
Psyence Biomedical Ltd. Warrant (PBMWW) invested $10K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Psyence Biomedical Ltd. Warrant's debt-to-equity ratio?
Psyence Biomedical Ltd. Warrant (PBMWW) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Psyence Biomedical Ltd. Warrant's return on assets (ROA)?
Psyence Biomedical Ltd. Warrant (PBMWW) had a return on assets of 13.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Are Psyence Biomedical Ltd. Warrant's earnings high quality?
For every $1 of reported earnings, Psyence Biomedical Ltd. Warrant (PBMWW) used $3.69 of operating cash (-$3.7M OCF vs $1.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.